GlassScriptPhysician profile
Stuart Alan Weprin
NPI 1154327088
$5,798.97
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,116 · 2020: $87.97 · 2021: $317 · 2022: $1,369 · 2023: $758 · 2024: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.22 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,760.09 | 2019 | |
| Pfizer INC. | $1,190.29 | 2019-2023 | |
| Gynesonics, INC. | $960.92 | 2022 | |
| Abbvie INC. | $374.58 | 2019-2024 | Liletta, Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $288.93 | 2019-2024 | Myrbetriq, Veozah |
| Channel Medsystems, INC. | $172.38 | 2022-2023 | |
| Amgen INC. | $134.96 | 2023-2024 | Prolia, Evenity |
| Coopersurgical, INC. | $112.88 | 2019-2023 | Paragard T 380a, Mara Console |
| Therapeuticsmd, INC. | $92.34 | 2019-2022 | |
| Daiichi Sankyo INC. | $90.02 | 2019-2022 | |
| Lupin INC. | $80.07 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $75.77 | 2019-2024 | Gardasil 9, Gardasil |
| Optumhealth Care Solutions, LLC | $61.73 | 2023-2024 | Vivify Health Care Team Portal 001, Eitan Medical, Vivify Health Care Team Portal |
| Myovant Sciences INC. | $59.01 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.46 | 2019-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $40.32 | 2022-2023 | |
| Amag Pharmaceuticals, INC. | $33.46 | 2019-2020 | |
| Allergan, INC. | $27.48 | 2019 | |
| Scynexis, INC. | $27.03 | 2022 | |
| Ethicon US, LLC | $26.93 | 2021 | |
| Organon LLC | $25.53 | 2021-2023 | Jada System |
| Mylan Pharmaceuticals INC. | $20.92 | 2021 | |
| Exeltis, USA INC. | $20.00 | 2023 | Slynd |
| Medtronic USA, INC. | $18.40 | 2019 | |
| Biogen, INC. | $16.39 | 2024 | |
| Hologic Sales and Service, LLC | $15.72 | 2023 | Aptima |
| Sumitomo Pharma America, INC. | $14.03 | 2023 | Myfembree |
| Ascend Therapeutics US, LLC | $11.33 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Weprin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.